These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38081992)

  • 41. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents.
    Fu CC; Chen MC; Li YM; Liu TT; Wang LY
    Ann Acad Med Singap; 2009 Jan; 38(1):15-7. PubMed ID: 19221666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triglyceride to high-density lipoprotein cholesterol ratio is an independent predictor of liver fibrosis among pediatrics non-alcoholic fatty liver disease.
    Ting YW; Jalaludin MY; Zaini AA; Mohamed R
    Front Endocrinol (Lausanne); 2022; 13():1071350. PubMed ID: 36589844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight/obese patients with NAFLD: a multicenter randomized controlled trial in China.
    Liu Z; Jin P; Liu Y; Zhang Z; Wu X; Weng M; Cao S; Wang Y; Zeng C; Yang R; Liu C; Sun P; Tian C; Li N; Zeng Q
    Nutr J; 2024 Jun; 23(1):64. PubMed ID: 38872173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
    Nakou ES; Filippatos TD; Georgoula M; Kiortsis DN; Tselepis AD; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2008 Jul; 24(7):1919-29. PubMed ID: 18513463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial.
    Tutunchi H; Arefhosseini S; Ebrahimi-Mameghani M
    Clin Nutr ESPEN; 2023 Apr; 54():412-420. PubMed ID: 36963888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carotid intima-media thickness and flow-mediated dilation in obese children with non-alcoholic fatty liver disease.
    Torun E; Aydın S; Gökçe S; Özgen İT; Donmez T; Cesur Y
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():92-8. PubMed ID: 25910377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
    Wang D; Nan N; Bing H; He B
    Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
    Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR
    J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults.
    Li S; Feng L; Ding J; Zhou W; Yuan T; Mao J
    BMC Gastroenterol; 2023 Nov; 23(1):376. PubMed ID: 37919650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta-analysis of randomized controlled trials.
    Haber R; Zarzour F; Ghezzawi M; Saadeh N; Bacha DS; Al Jebbawi L; Chakhtoura M; Mantzoros CS
    Diabetes Obes Metab; 2024 May; 26(5):1850-1867. PubMed ID: 38468148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
    Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
    Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.
    Polyzos SA; Goulis DG; Giouleme O; Germanidis GS; Goulas A
    Curr Obes Rep; 2022 Sep; 11(3):166-179. PubMed ID: 35501557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children.
    Kodhelaj K; Resuli B; Petrela E; Malaj V; Jaze H
    Minerva Pediatr; 2014 Feb; 66(1):23-30. PubMed ID: 24608579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thyroid hormone levels in obese children and adolescents with non-alcoholic fatty liver disease.
    Torun E; Özgen IT; Gökçe S; Aydın S; Cesur Y
    J Clin Res Pediatr Endocrinol; 2014; 6(1):34-9. PubMed ID: 24637308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.